M-Insightlogo
  • Multiple Myeloma & MRD
    dropmenu
    What is Multiple Myeloma?
    MM is a blood cancer characterized by the clonal expansion of plasma cells in the bone marrow. Myeloma is rare, accounting for 1% of all cancers.
    dropmenu
    MM diagnosis and monitoring
    Multiple myeloma diagnosis and monitoring are based on clinical symptoms and a variety of laboratory tests. M-protein detection and quantification are integral parts of diagnosis and monitoring of MM.
    dropmenu
    What is MRD ?
    MRD stands for Minimal Residual Disease. It refers to the very small number of myeloma cells that are present in the bone marrow after treatment. These remaining cells often cannot be detected through traditional tests of treatment response. However, they have the potential to multiply and cause relapse.
  • M-inSight®
  • Resources
  • About us
    dropmenu
    Corgenix
    CAP/CLIA Clinical Laboratory: Precision disease monitoring tools powered by advanced proteomics and clinical excellence.
    dropmenu
    Meet the M-inSight® Team
    M-inSight® was developed by a team of myeloma experts and scientific innovators committed to improving how patients are monitored—using advanced technology to deliver clearer, less invasive testing.
    dropmenu
    Sebia
    Center of Excellence for Research and Development: Our mission is to create advanced tools that translate complex biological signals from the patient’s body into clear, interpretable data.
  • Contact us
  • How to order?
    • Order M-inSight®
  • Multiple Myeloma & MRD
  • M-inSight®
  • Resources
  • About us
  • Contact us
  • How to order?
  • Order M-inSight®
  • Back
  • What is Multiple Myeloma?
  • MM diagnosis and monitoring
  • What is MRD ?
  • Back
  • Corgenix
  • Meet the M-inSight® Team
  • Sebia

Author: cbernier@sebia.com

September 2026

State-specific laboratory certificates and licenses
July 2026

COMy 2026 Sebia Symposium – MRD 2.0 : Minimal Invasion, Maximum Insight
June 2026

Peripheral Blood Clonotypic Mass Spectrometry-Based MRD Stratification Identifies Patients – IMS 2025
February 2026

Clonotypic Peptide MS to monitor M-Protein reduction in Patients with relapsed/refractory MM from IKEMA study – ASH 2025
August 2025

CAP/CLIA Accreditation for Laboratory Services
June 2025

International Myeloma Society – IMS 2025
February 2025

European Myeloma Network Meeting – EMN 2025
February 2025

Monitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients with MM – Pharmaceutics 2025
January 2025

Clonotypic Peptide Mass Spectrometry to Define Functional Cure in Patients with Multiple Myeloma Undergoing Maintenance Cessation – ASH 2024
November 2024

American Society of Hematology – ASH 2024
  • 1
  • 2
  • 3
  • 4
  • Suivant
See what others can't
Order M-inSight®

Multiple Myeloma & MRD

Multiple Myeloma MRD Monitoring Diagnosis and Monitoring

M-inSight®

Discover M-inSight® Ordering information Resources Contact us
© 2026 M-inSight®
Terms of Use
Privacy policy
Privacy Practices
Claims presented in the website are supported by references on the Resources page.